Adapting low-dose buprenorphine induction to meet patient needs: A pilot study

Adapting low-dose buprenorphine induction to meet patient needs: A pilot study

Introduction: Low-dose buprenorphine induction (LDBI) has been proposed to initiate buprenorphine in patients who are taking full opioid agonists in order to limit the risk of precipitated withdrawal. The objective of this study was to understand how real-world patient-specific adjustments in LDBI p...

Full description

Bibliographic Details
Main Authors:	Zoe A. Karavolis, Payel J. Roy
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Drug and Alcohol Dependence Reports
Subjects:	Buprenorphine Buprenorphine/naloxone Opioid use disorder Induction
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772724622000798

Similar Items

Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use
by: Erin L. Winstanley, et al.
Published: (2022-12-01)

Implementation of an education session on buprenorphine induction in the emergency department, a resident-led initiative
by: Cara Marie Borelli, et al.
Published: (2024-01-01)

Low-dose buprenorphine initiation during pregnancy: a case report
by: Shivania Reddy, BSc, et al.
Published: (2024-02-01)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
by: Hassan Ziaaddini, et al.
Published: (2018-12-01)

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach
by: Jennifer Rozylo, et al.
Published: (2020-01-01)

Buprenorphine/naloxone – one formulation that doesn’t fit all: a case report
by: Hannan M. Braun, et al.
Published: (2024-07-01)

Buprenorphine Induction Using Microdosing for the Management of Opioid Use Disorder in Pregnancy
by: Neil B. Patel, et al.
Published: (2024-01-01)

Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design
by: Payel Jhoom Roy, et al.
Published: (2023-03-01)

Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic
by: David Dadiomov, et al.
Published: (2022-06-01)

Patients' perspectives on buprenorphine subcutaneous implant: a case series
by: Claudio Pierlorenzi, et al.
Published: (2024-04-01)

Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature
by: Alice Ordean, et al.
Published: (2023-02-01)

Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: an updated systematic review
by: Kathleen K. Adams, et al.
Published: (2025-02-01)

Policies, adaptations, and ongoing challenges to naloxone, buprenorphine and nonprescription syringe access across four-states: Findings from an environmental scan and key informant interviews
by: Anthony S. Floyd, et al.
Published: (2024-06-01)

Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study
by: Benjamin L. H. Jones, et al.
Published: (2024-04-01)

Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization
by: Meng Gu, et al.
Published: (2023-01-01)

Sociodemographic and clinical characteristics of patients with long-term remission with buprenorphine / naloxone in opiate use disorder
by: Y. Kahya, et al.
Published: (2021-04-01)

Reduced emergency department use among insured individuals receiving extended-release buprenorphine in a health system setting
by: Bobbi Jo H. Yarborough, et al.
Published: (2024-06-01)

Breaking barriers: Assessing the feasibility and acceptability of telemedicine-assisted buprenorphine induction for opioid use disorder in India
by: Abhishek Ghosh, et al.
Published: (2024-10-01)

The association of medical providers’ attitudes about naloxone and treating people with opioid use disorder and their self-reported low-barrier treatment practices
by: Rachel P. Winograd, et al.
Published: (2023-12-01)

Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone
by: Lindsay M. Mailloux, PharmD, et al.
Published: (2021-01-01)

Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study
by: Travis M. Scott, et al.
Published: (2017-11-01)

Jail-based interventions to reduce risk for opioid-related overdose deaths: Examples of implementation within Ohio counties participating in the HEALing Communities Study
by: Joel Sprunger, et al.
Published: (2024-12-01)

Editorial: Reviews in opioid use disorders
by: Wendy Walwyn, et al.
Published: (2024-08-01)

The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review
by: Colleen G. Jordan, et al.
Published: (2022-04-01)

Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial
by: Hannah Ellerbroek, et al.
Published: (2022-09-01)

Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
by: Venumadhav Janganati, et al.
Published: (2023-05-01)

Buprenorphine/naloxone initiation in the emergency department: A series of vignettes
by: Margarita Popova, et al.
Published: (2024-12-01)

Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series
by: John P. Murray, et al.
Published: (2023-06-01)

Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder
by: Laura Szczesniak, et al.
Published: (2024-06-01)

Primary care management of Long-Term opioid therapy
by: Phillip O. Coffin, et al.
Published: (2022-12-01)

Large variations in all-cause and overdose mortality among >13,000 patients in and out of opioid maintenance treatment in different settings: a comparative registry linkage study
by: Roman Gabrhelík, et al.
Published: (2023-09-01)

Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018
by: Kevin P. Conway, et al.
Published: (2022-01-01)

Patient acceptance of emergency department-initiated buprenorphine and reasons for declining
by: Lindsey K. Jennings, et al.
Published: (2025-03-01)

Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report
by: Menard Shannon PharmD, et al.
Published: (2021-11-01)

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
by: Megan K Reed, et al.
Published: (2022-12-01)

An Indigenous-led buprenorphine-naloxone treatment program to address opioid use in remote Northern Canada
by: Aleksandra M. Zuk, et al.
Published: (2024-12-01)

Rates of buprenorphine prescribing and racial disparities among patients with opioid overdose
by: Kimberly Y. Chieh, et al.
Published: (2024-12-01)

Rapid induction onto extended-release injectable buprenorphine following opioid overdose: A case series
by: Taylor A. Ochalek, et al.
Published: (2023-06-01)

Association of chronic non-cancer pain status and buprenorphine treatment retention among individuals with opioid use disorder: Results from electronic health record data
by: William S. John, et al.
Published: (2022-06-01)

Management of buprenorphine/naloxone therapy in substances abuse consumers in prison: efficacy and safety
by: Felice A. Nava
Published: (2018-11-01)